5 February
2025
Fevertree Drinks
plc
("Fever-Tree" or the
"Company")
Completion of Share Issuance
to Molson Coors
Fevertree Drinks plc ("Fever-Tree" or the "Company") announces today the
completion of the issuance of equity to Molson Coors Beverage
Company ("Molson Coors")
following the announcement of the strategic partnership between
Fever-Tree and Molson Coors on 30 January 2025.
As announced on 30 January 2025, the
equity issuance of ordinary shares of £0.0025 each in the Company
("Ordinary Shares")
comprises the issuance of 10,856,628 Ordinary Shares (the
"Issuance Shares") in the
Company at an issue price of 654.2 pence per Ordinary Share
(together, the "Issuance").
Application has been made for the
Issuance Shares to be admitted to trading on AIM ("Admission"). It is expected that
Admission will become effective at 8.00 a.m. today, 5 February
2025. The Issuance Shares will be issued credited as fully paid and
will rank pari passu in all respects with the existing Ordinary
Shares.
Following Admission, the total
number of Ordinary Shares in issue will be 127,615,093. The Company
does not hold any Ordinary Shares in treasury. Therefore, the total
number of Ordinary Shares with voting rights will be 127,615,093.
This figure may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the share capital of the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.
The resultant new significant
shareholdings in the Company, following completion of the Issuance,
are set out below.
|
Name
|
Previous holding
|
Previous percentage holding of
issued share capital
|
Resultant holding
|
Resultant percentage holding of
enlarged issued share capital on Admission
|
|
Molson Coors Beverage
Company
|
-
|
-
|
10,856,628
|
8.5%
|
For
further information:
Fever-Tree
Investor queries
Ann Morris-Gibbons, Director of
Investor Relations I ann.hyams@fever-tree.com
I +44 (0)7435 828 138
Media queries
Oliver Winters, Director of
Communications I oliver.winters@fever-tree.com
I +44 (0)770 332 9024
Nominated Advisor and Broker - Investec Bank
plc
David Flin I +44 (0)20 7597
5970
Financial Adviser & Corporate Broker - Morgan Stanley
& Co. International plc
Henry Stewart I Andrew Foster I
Jessica Pauley I +44 (0)20 7425 8000
Corporate Broker - Jefferies International
Limited
Ed Matthews I Richard Taylor I +44
(0)20 7029 8000
Financial PR advisers -
FGS Global
Faeth Birch +44 (0)7768 943 171;
Anjali Unnikrishnan +44 (0) 7826 534 233
About Fever-Tree:
Fever-Tree is the world's leading
supplier of premium carbonated mixers for alcoholic spirits by
retail sales value, with distribution to over 90 countries
worldwide. Based in the UK, the brand was launched in 2005 to
provide high quality mixers which could cater to the growing demand
for premium spirits, in particular gin, but also increasingly for
vodka, rum and whisky. The Company sells a range of carbonated
mixers to hotels, restaurants, bars and cafes ("On Trade") as well
as selected retail outlets ("Off Trade").
Forward-looking statements
This Announcement may contain
certain statements about the future outlook for Fever-Tree.
Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be
influenced by factors that could cause actual outcomes and results
to be materially different.
Additional information
This Announcement is made for
information purposes only and does not constitute an offer to sell
or issue or solicitation to buy, subscribe for or otherwise acquire
shares in Fevertree Drinks plc in any jurisdiction in which any
such offer or solicitation would be unlawful.
The securities discussed herein are
not and will not be registered under the US Securities Act of 1933,
as amended (the "Securities Act"), and may not be offered or sold
in the United States, unless registered under the Securities Act,
or pursuant to an exemption from, or in a transaction not subject
to, registration under the Securities Act. No public offering of
the securities discussed herein is being made in the United States
and the information contained herein does not constitute an
offering of securities for sale in the United States and the
Company does not currently intend to register any securities under
the Securities Act.
